We investigated the efficacy of real-time continuous glucose monitoring (rtCGM) and intermittently scanned continuous glucose monitoring (isCGM) on change in A1C. CORRIDA LIFE was a 12 month, real-world, non-randomized trial that assessed the impact of rtCGM (Dexcom G5 or G6) vs. isCGM (FreeStyle Libre 14-Day, Abbott) on A1C and other CGM metrics in adults with T1D. Patients on MDI therapy or CSII with no automatic functions were included. One hundred ninety-one adults with T1D (mean age 40±13 years, A1C 8.1±3.4% [65±14 mmol/mol]) participated in this study; 81 patients initiated rtCGM and 110 initiated isCGM. After 12-months, A1C was significantly lower with rtCGM vs. isCGM (7.1±3.1% [54.1±10.1 mmol/mol] vs. 7.7±3.3% [61.2±12.2 mmol/mol]) , p=0.0001. (Figure 1) The percentage of time in hypoglycemia (<70 mg/dL [<3.9 mmol/L]) was lower among rtCGM vs. isCGM participants (4.3±2.8% vs. 6.4±5.3%) , p=0.003) . Patients with rtCGM spent less time in clinically significant hypoglycemia (<54 mg/dL [<3.0 mmol/L]) (0.9±1.0% vs. 2.3±2.5%, p<0.0001) and more time in target range (70-180 mg/dL [3.9-10 mmol/L]) than isCGM users (67.5±14.8% vs. 57.8±17.0%) , p=0.0002. Use of rtCGM was superior to isCGM in reducing A1C and hypoglycemia and improving other glycemic outcomes.

graphic
View largeDownload slide
Disclosure

L. Radovnická: Consultant; Medtronic, Speaker’s Bureau; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Sanofi. M. Prazny: Advisory Panel; Bayer AG, Consultant; Boehringer Ingelheim International GmbH, Speaker’s Bureau; Abbott Diabetes, Amgen Inc., Eli Lilly and Company, Medtronic, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Novo Nordisk, Sanofi. J. Soupal: Advisory Panel; Abbott Diabetes, Roche Diabetes Care, Speaker’s Bureau; Boehringer Ingelheim International GmbH, Dexcom, Inc., Lilly Diabetes, Medtronic, Novo Nordisk. A. Hásková: None. Q. Do: None. E. Horova: None. V. Navrátilová: None. O. Mikes: None. D. Cihlár: None. C. Parkin: Consultant; Abbott Diabetes, CeQur SA, Dexcom, Inc., LifeScan, MannKind Corporation, Novo Nordisk, Provention Bio, Inc., Roche Diabetes Care. G. Grunberger: Advisory Panel; LifeScan, Nevro Corp., Research Support; Medtronic, Speaker’s Bureau; Abbott Diabetes, Eli Lilly and Company, Novo Nordisk.

Funding

Ministry of Health, Czech Republic, General University Hospital in Prague

© 2022 by the American Diabetes Association
2022
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.